LSD1 is the vital regulator involved in the growth of common non-melanoma skin cancers, according to a new study done by the researchers in the Perelman School of Medicine at the University of Pennsylvania. The journal Cell Reports published the findings.
The outer layer of the skin completely replaces itself every two to four weeks, but when this process is blocked, cancer can grow. Blocking LSD1 could be an effective, targeted treatment method for those cancers, which are the most common in the world.
Cutaneous squamous cell carcinoma (cSCC) is a skin cancer caused by the abnormal growth of skin cells. Together with a similar type of cancer known as basal cell carcinoma (BCC), they outnumber all other human cancers combined.
"Our study shows that targeting LSD1 can force the skin cells down a differentiation path, which could open the door to new topical therapies that can ultimately turn tumor cells into healthier, more normal cells," said the study's senior author Brian C. Capell, MD, PhD, an assistant professor of Dermatology and a member of Penn's Epigenetics Institute and Abramson Cancer Center. The co-lead authors on the study are Shaun Egolf, a graduate student, and Yann Aubert, PhD, a postdoctoral fellow, both in Capell's lab.
LSD1 is typically elevated in many types of cancer, and there are several inhibitors that attempt to target it. But until now, no one has shown its role in repressing the genes the skin needs for healthy turnover. That knowledge could open the door to a new treatment method that blocks LSD1 with a skin cream or other topical therapy.
"By knocking out LSD1, we can essentially turn the switch back on that would tell the skin to differentiate in a healthy way," Capell said.
Researchers say work is already underway to prove the concept can work, which would pave the way for human clinical trials.